Drywall works for the DAK-Gesundheit headquarters in Hamburg and the academy in Bad Segeberg.
Name
DAK-Gesundheit
City
Hamburg
Country
DE
Procedure Type
de-open
Contract Type
Works
Main CPV
45000000, Construction work.
Legal Basis
de-vob
Submission Deadline
24 days remaining(LOT-0000)
Published
Conclusion of non-exclusive rebate agreements according to § 130a Abs. 8 SGB V for medicinal products containing the active substance Betamethasone + Clotrimazole (ATC D01AC20): Term from 01.09.2026 to 31.08.2028, with an extension option of 1x12 months. Any pharmaceutical company can join at any time under the same conditions during the contract term. Required documents include an offer letter, acceptance of the contractual terms and rebates, and completed Annexes 1 and 2 listing the medicinal products. Submission of documents is via email to openhouse@dak.de, with Annex 2 as an Excel file. For a contract start on 01.09.2026, documents must be submitted by the 5th of the preceding month; later entries are possible for the 1st or 15th of the following month if documents are submitted by the 5th of the preceding month.
DAK-Gesundheit
·HamburgConclusion of non-exclusive discount agreements for the active ingredient Olanzapine (TRS dosage form only), ATC N05AH03. Any pharmaceutical company can conclude a framework agreement under the same conditions during the contract term. The contract term begins on 01.09.2026 and ends on 31.08.2028, with an extension option of 1x12 months. For contract conclusion or later accession, an offer letter, acknowledgment of contractual terms and discounts, and completed Annexes 1 and 2 (Excel file) must be submitted via email to openhouse@dak.de. For accession on 01.09.2026 or on the 1st or 15th of a subsequent month, documents must be submitted by the 5th of the preceding month. This procedure is not subject to cartel procurement law.
DAK-Gesundheit
·HamburgNon-exclusive discount agreement for the active ingredient Oxybutynin (PFT dosage form only), ATC G04BD04: Contract period from 01.09.2026 to 31.08.2028, with one extension option of 1x12 months. Any pharmaceutical company can conclude a framework agreement at any time under the same conditions. Required documents include a letter of offer, acceptance of the contractual terms and discounts, and completed Annexes 1 and 2, in which the medicines containing the active ingredient must be entered. Documents must be submitted via email to openhouse@dak.de, with Annex 2 to be sent as an Excel file. For a contract start on 01.09.2026, documents must be submitted by the 5th of the preceding month. Later entries are possible at any time; for an entry on the 1st or 15th of the following month, documents must be submitted by the 5th of the preceding month. further items as per the tender documents.
DAK-Gesundheit
·HamburgNon-exclusive rebate agreement for the active ingredient Brivaracetam (ATC N03AX23): Conclusion of a framework agreement for pharmaceutical companies under equal conditions, with a term from 01.09.2026 to 31.08.2028 and an extension option of 1x12 months. Submission of documents (offer letter, recognized contract with rebates, completed annexes 1 and 2, annex 2 as an Excel file) is via email to openhouse@dak.de. For a contract start on 01.09.2026, documents must be submitted by the 5th of the preceding month; later entries on the 1st or 15th of the following month require submission by the 5th of the preceding month. The procedure automatically ends upon the entry into force of an exclusive contract; further items as per the tender documents.
DAK-Gesundheit
·HamburgWith Patterno-HIT, receive relevant tenders daily, automatically filtered to your company profile.
Book Demo Now